PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-16.18%
G&A reduction while AGEN shows 6.25% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
7.12%
Other expenses growth while AGEN reduces costs. John Neff would investigate differences.
-22.68%
Operating expenses reduction while AGEN shows 6.25% growth. Joel Greenblatt would examine advantage.
-22.68%
Total costs reduction while AGEN shows 1.02% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
7.12%
D&A growth while AGEN reduces D&A. John Neff would investigate differences.
22.73%
EBITDA growth below 50% of AGEN's 65.09%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
22.68%
Operating income growth below 50% of AGEN's 60.31%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
26.92%
Similar other expenses growth to AGEN's 31.01%. Walter Schloss would investigate industry patterns.
22.99%
Pre-tax income growth below 50% of AGEN's 53.55%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth while AGEN reduces burden. John Neff would investigate differences.
22.99%
Net income growth below 50% of AGEN's 54.43%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
38.32%
EPS growth 50-75% of AGEN's 55.71%. Martin Whitman would scrutinize operations.
38.32%
Diluted EPS growth 50-75% of AGEN's 55.59%. Martin Whitman would scrutinize operations.
24.80%
Share count reduction below 50% of AGEN's 2.80%. Michael Burry would check for concerns.
24.80%
Diluted share reduction below 50% of AGEN's 2.47%. Michael Burry would check for concerns.